Olema Slides as AstraZeneca Breast Cancer Trial Misses Goal
Investors marked down Olema after AstraZeneca’s SERENA-4 setback raised fresh questions about oral SERD drugs in breast cancer.
Makkler Newsroom · Sep 16, 03:15 AM · 2 min read
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO